Development of a functional outcome measure for riboflavin transporter deficiency

被引:1
|
作者
Fennessy, Jack R. [1 ]
Donlevy, Gabrielle A. [1 ,2 ]
Mckay, Marnee J. [1 ]
Burns, Joshua [1 ,2 ]
Cornett, Kayla M. D. [1 ,2 ]
Menezes, Manoj P. [3 ,4 ,5 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Sch Hlth Sci, Sydney, NSW, Australia
[2] Sydney Childrens Hosp Network, Paediat Gait Anal Serv New South Wales, Westmead, NSW, Australia
[3] Univ Sydney, Westmead Clin Sch, Fac Med & Hlth, Childrens Hosp, Sydney, NSW, Australia
[4] Childrens Hosp Westmead, TY Nelson Dept Neurol & Neurosurg, Sydney, NSW, Australia
[5] Childrens Hosp Westmead, TY Nelson Dept Neurol & Neurosurg, Westmead, NSW 2145, Australia
关键词
clinical outcome assessment; clinical trials; endpoint; performance outcome measure; riboflavin transporter deficiency; MARIE-TOOTH DISEASE; REFERENCE VALUES; MUTATIONS; VARIABILITY; VALIDATION; SCALE;
D O I
10.1111/jns.12619
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and AimsRiboflavin transporter deficiency (RTD) is a progressive inherited neuropathy of childhood onset, characterised clinically by pontobulbar palsy, sensory ataxia, sensorineural deafness, muscle weakness, optic atrophy and respiratory failure. A robust and responsive functional outcome measure is essential for future clinical trials of disease-modifying therapies including genetic therapies. The Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS) is a well-validated outcome measure for CMT and related neuropathies, and might have utility for measuring disease progression in individuals with RTD. However, the CMTPedS requires modifications to account for phenotypic differences between children with CMT and RTD. The aim of this study was to develop a functional outcome measure based on the CMTPedS for specific use in individuals with RTD.MethodsThe CMTPedS data collected over the last 10 years in individuals with RTD attending the Peripheral Neuropathy Management Clinic at the Children's Hospital at Westmead (Sydney, Australia) were reviewed to evaluate each item within the CMTPedS. A literature review of articles published until September 2021 for functional outcome measures generated an item pool for pilot testing. The results of this pilot testing, alongside analysis of existing CMTPedS item scores in the RTD cohort, informed the modification of the CMTPedS.ResultsCMTPedS data were reviewed for eight individuals over the past 10 years. Two items were identified as requiring modification or removal and additional items of proximal strength and function needed to be considered. Six studies were identified in the literature review, and five items were selected for pilot testing. 'Shoulder internal rotation' and the '30-s sit to stand test' were added as proximal measures of strength and function. The composite balance item comprising nine tasks in the CMTPedS showed a ceiling effect and was replaced with the single 'Feet apart on a line eyes open' balance item. 'Pinprick sensation' was removed due to a floor effect.InterpretationThis study provides preliminary evidence that the Riboflavin Transporter Deficiency Pediatric Scale (RTDPedS) is a functional outcome measure covering strength, upper and lower limb function, balance and mobility for individuals with RTD to assess disease severity and progression in clinical trials and cohort studies.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
  • [41] RIBOFLAVIN TRANSPORTER DEFICIENCY: A RARE, TREATABLE DISORDER THAT HAS POTENTIAL TO BE DETECTED ON THE NEWBORN SCREEN
    Feitosa, Daniela
    Fox, Charlene
    Weiss-Burns, Jody
    Galvin-Parton, Patricia
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (03) : 230 - 231
  • [42] A riboflavin transporter deficiency presenting as pure red cell aplasia: a pediatric case report
    Cheng, Jingying
    Yao, Jiafeng
    Zhao, Shasha
    Fu, Lingling
    Zhang, Liqiang
    Jiang, Jin
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [43] Caspase-dependent apoptosis in Riboflavin Transporter Deficiency iPSCs and derived motor neurons
    Chiara Marioli
    Maurizio Muzzi
    Fiorella Colasuonno
    Cristian Fiorucci
    Nicolò Cicolani
    Stefania Petrini
    Enrico Bertini
    Marco Tartaglia
    Claudia Compagnucci
    Sandra Moreno
    Cell Death Discovery, 10
  • [44] Hematologic presentation and the role of untargeted metabolomics analysis in monitoring treatment for riboflavin transporter deficiency
    Pillai, Nishitha R.
    Amin, Hitha
    Gijavanekar, Charul
    Liu, Ning
    Issaq, Niveen
    Broniowska, Katarzyna A.
    Bertuch, Alison A.
    Sutton, V. Reid
    Elsea, Sarah H.
    Scaglia, Fernando
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2020, 182 (11) : 2781 - 2787
  • [45] Identification and Functional Characterization of Novel Mammalian Riboflavin Transporter RFT1
    Yonezawa, Atsushi
    Masuda, Satohiro
    Katsura, Toshiya
    Inui, Ken-ichi
    DRUG METABOLISM REVIEWS, 2009, 41 : 61 - 61
  • [46] The Spine Functional Index: development and clinimetric validation of a new whole-spine functional outcome measure
    Gabel, Charles P.
    Melloh, Markus
    Burkett, Brendan
    Michener, Lori A.
    SPINE JOURNAL, 2019, 19 (02): : E19 - E27
  • [47] Riboflavin transporter is finally identified
    Moriyama, Yoshinori
    JOURNAL OF BIOCHEMISTRY, 2011, 150 (04): : 341 - 343
  • [48] Development and validation of the quality of life outcome measure (questionnaire) for chronic anterior cruciate ligament deficiency
    Mohtadi, N
    AMERICAN JOURNAL OF SPORTS MEDICINE, 1998, 26 (03): : 350 - 359
  • [49] Creatine transporter deficiency: Novel mutations and functional studies
    Ardon, O.
    Procter, M.
    Mao, R.
    Longo, N.
    Landau, Y. E.
    Shilon-Hadass, A.
    Gabis, L. V.
    Hoffmann, C.
    Tzadok, M.
    Heimer, G.
    Sada, S.
    Ben-Zeev, B.
    Anikster, Y.
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 8 : 20 - 23